Close Menu

NEW YORK (GenomeWeb) – UK-based clinical decision support technology developer Congenica said today that it has raised nearly £13.3 million ($17.3 million) in an extension of its Series B funding round. The new investment brings the Series B total to £23.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.

Dec
04
Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).

Dec
05
Sponsored by
Amazon

The discovery of microbial cell-free DNA has propelled the introduction of new technologies that can be leveraged for next-generation diagnostic assays. Previously inaccessible genomic information can now be comprehensively surveyed for microorganisms, all from a single blood draw.

Dec
10
Sponsored by
Congenica II

This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.

Dec
11
Sponsored by
Roche

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.